scholarly article | Q13442814 |
P50 | author | Lu Gao | Q56574163 |
P2093 | author name string | Bing Xing | |
Yijun Wu | |||
Xiaopeng Guo | |||
Zihao Wang | |||
Chenzhe Feng | |||
P2860 | cites work | Hot topics and trends in cardiovascular research | Q92512959 |
Genetic and molecular epidemiology of adult diffuse glioma | Q92948858 | ||
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015 | Q93177223 | ||
IDH1 and IDH2 mutations in gliomas | Q24648948 | ||
Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
Overcoming therapeutic resistance in glioblastoma: the way forward | Q29248396 | ||
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma | Q29617568 | ||
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis | Q29619677 | ||
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group | Q30584392 | ||
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...] | Q33247166 | ||
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial | Q34519250 | ||
Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. | Q34691513 | ||
Publication analysis on insomnia: how much has been done in the past two decades? | Q35633073 | ||
Psychosocial and supportive-care needs in high-grade glioma | Q37257131 | ||
Glioblastoma research 2006-2010: pattern of citation and systematic review of highly cited articles | Q38003778 | ||
Contribution of case reports to glioblastoma research: systematic review and analysis of pattern of citation | Q38017692 | ||
Clinical Natural Language Processing in 2015: Leveraging the Variety of Texts of Clinical Interest | Q38384891 | ||
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary | Q38829244 | ||
Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial | Q44647852 | ||
Functional outcome after language mapping for glioma resection | Q46089878 | ||
Hospice Utilization in Patients with Malignant Gliomas | Q47605807 | ||
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. | Q48493738 | ||
WHO 2016 Classification of gliomas. | Q50501884 | ||
A bibliometric analysis of natural language processing in medical research. | Q52626036 | ||
The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? | Q52666757 | ||
A Bibliometric Analysis of the Landscape of Cancer Rehabilitation Research (1992-2016) | Q57172785 | ||
The New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: Organization, Objectives, and Activities | Q73667035 | ||
The top 50 most-cited articles on low-grade glioma: a bibliometric analysis | Q91016739 | ||
Challenges to curing primary brain tumours | Q91410839 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P304 | page(s) | 1463 | |
P577 | publication date | 2019-01-01 | |
P1433 | published in | Frontiers in Oncology | Q26839986 |
P1476 | title | Publication Landscape Analysis on Gliomas: How Much Has Been Done in the Past 25 Years? | |
P478 | volume | 9 |
Q98386271 | A bibliometric analysis of 23,492 publications on rectal cancer by machine learning: basic medical research is needed | cites work | P2860 |
Search more.